StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 11/3056% above fair value
$30.67+0.15 (+0.49%)

Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%

Pfizer Sulperazon (cefoperazone/sulbactam by Year

Sulperazon (cefoperazone/sulbactam — hospital anti-infective) — International revenues ($M) ($M)

QuarterlyAnnual

Pfizer Sulperazon (cefoperazone/sulbactam: $653M in FY2025, up 2.5% from a year earlier.

Latest, FY2025
653
Period ended Dec 31, 2025
Change on a year earlier
+2.5%
637 in FY2024
History
10 years
Since FY2016
Sources
9
Documents cited below

Where the FY2025 figure comes from

“|| Sulperazon (Outside the U.S. and Canada) | 653 | 637 | 2% | 3% | — | — | — | 653 | 637 | 2% | 3%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedSulperazon (cefoperazone/sulbactam — hospital anti-infective) — International revenues ($M) ($M)Year on yearSource
FY2025Dec 31, 2025653+2.5%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2024Dec 31, 2024637-15.9%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2023Dec 31, 2023757+0.1%Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
FY2022Dec 31, 2022756-3.3%Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
FY2021Dec 31, 2021782+15.5%Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗
FY2020Dec 31, 2020677+11.0%Form 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗
FY2019Dec 31, 2019610-9.6%Form 8-K (Earnings / Guidance Release) (pfe-12312020xex99.htm, filed 2021-02-02) ↗
FY2018Dec 31, 2018675+43.3%Form 8-K (Earnings / Guidance Release) (pfe-12312019xex99.htm, filed 2020-01-28) ↗
FY2017Dec 31, 2017471+18.9%Form 8-K (Earnings / Guidance Release) (pfe-12312018xex99.htm, filed 2019-01-29) ↗
FY2016Dec 31, 2016396–Form 8-K (Earnings / Guidance Release) (pfe-12312017xex99.htm, filed 2018-01-30) ↗

Breakdown

What makes up sulperazon (cefoperazone/sulbactam

Cite this data

StockData. (2026). Pfizer Sulperazon (cefoperazone/sulbactam ($M), annual FY2016–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/sulperazon-intl

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.